BEAM - Beam Therapeutics Inc Stock Price, Fair Value and News

$26.73+3.36 (+14.38%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BEAM Price Action

Last 7 days

6.8%

Last 30 days

10.2%

Last 90 days

44.2%

Trailing 12 Months

2.9%

BEAM RSI Chart

BEAM Valuation

Market Cap

2.7B

Price/Earnings (Trailing)

-6.54

Price/Sales (Trailing)

48.7

EV/EBITDA

-6.42

Price/Free Cashflow

-7.7

BEAM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BEAM Fundamentals

BEAM Revenue

Revenue (TTM)

55.7M

Rev. Growth (Yr)

-32.03%

Rev. Growth (Qtr)

14.55%

BEAM Earnings

Earnings (TTM)

-414.6M

Earnings Growth (Yr)

-16.61%

Earnings Growth (Qtr)

-10.2%

BEAM Profitability

EBT Margin

-721.78%

Return on Equity

-42.92%

Return on Assets

-31.63%

Free Cashflow Yield

-12.99%

BEAM Investor Care

Shares Dilution (1Y)

22.55%

Diluted EPS (TTM)

-4.43

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	63.6M	60.3M	55.7M	0
2024	299.2M	220.6M	142.1M	63.5M
2023	76.7M	80.2M	81.6M	377.7M
2022	54.1M	56.4M	58.7M	60.9M
2021	13.0M	25.9M	38.9M	51.8M
2020	0	0	0	24.0K
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CEO	Mr. John M. Evans M.B.A.
WEBSITE	https://beamtx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	532

Beam Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Beam Therapeutics Inc? What does BEAM stand for in stocks?

BEAM is the stock ticker symbol of Beam Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Beam Therapeutics Inc (BEAM)?

As of Wed Dec 03 2025, market cap of Beam Therapeutics Inc is 2.71 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BEAM stock?

You can check BEAM's fair value in chart for subscribers.

Is Beam Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether BEAM is over valued or under valued. Whether Beam Therapeutics Inc is cheap or expensive depends on the assumptions which impact Beam Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BEAM.

What is Beam Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, BEAM's PE ratio (Price to Earnings) is -6.54 and Price to Sales (PS) ratio is 48.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BEAM PE ratio will change depending on the future growth rate expectations of investors.